• OTLK is trading 5% down at $1.60 today, likely due to profit-taking after its recent rally.
  • The rally was driven by the FDA's acceptance of the resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA™ with a PDUFA target action date of July 29, 2026.
  • Additionally, the company recently regained compliance with Nasdaq's minimum bid price requirement on June 26, 2026.